AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKS FOR JUNE 2025
Aimia's NCIB is a component of the Company's strategy for enhancing shareholder value and reducing the discount of its share price relative to the intrinsic value of its net assets.
Shares repurchased in June were at a weighted-average price of $2.77 per common share for a total settlement of $2,996,163 excluding brokerage fees.
Through June 30, 2025, Aimia has repurchased and cancelled 6,669,332 common shares since it first announced its share buyback initiative on June 4, 2024 1.
On June 4, 2025 Aimia announced the renewal of its NCIB through June 5, 2026 with approval to purchase for cancellation up to 5,906,629 of its common shares.
Aimia believes that the market price of its common shares may, from time to time, not reflect the intrinsic value of the company, and that repurchases of common shares pursuant to the NCIB may represent an appropriate and desirable use of the Company's funds. Therefore, Aimia believes that it is in its best interest to proceed with this NCIB, while maintaining sufficient financial flexibility to execute on the Company's future strategic direction and capital allocation priorities.
About Aimia
Aimia Inc. (TSX: AIM) is a diversified company focused on enhancing the value of its two core global businesses, Bozzetto, a sustainable specialty chemicals company, and Cortland International, a rope and netting solutions company. Headquartered in Toronto, Aimia's priorities include reducing its holding company costs, reducing the discount of its share price to the intrinsic value of its net assets and efficiently utilizing its loss carry-forwards to create shareholder value.
For more information about Aimia, visit www.aimia.com
SOURCE Aimia Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
Lotto Max - A $75 million jackpot and an estimated 12 Maxmillions in the next draw Français
MONTRÉAL, Aug. 16, 2025 /CNW/ - In the next Lotto Max draw, slated for Tuesday, August 19, the prize pool will be $87 million and include a $75 million jackpot and an estimated 12 Maxmillions. Lotto Max continues to churn out winners in Québec Lotto Max players in Québec have won over $4.009 billion since its launch in 2009. In total, there have been 48 jackpot wins in the province, including 3 of $70,000,000—the largest jackpots ever won in Québec—in the February 25 and October 9, 2020, and June 7, 2022, draws. One $65,000,000 jackpot, four $60,000,000 jackpots, five $55,000,000 jackpots, and nine $50,000,000 jackpots have also been won in Quebec. In addition to these jackpot wins, Lotto Max players in Québec have also won a total of 248 Maxmillions prizes, each worth $1 million, and 151 shares of Maxmillions prizes. Draw results are available online at About Loto-Québec Loto-Québec has been delivering entertainment to Quebecers for over 50 years, and its operations benefit Québec as a whole. Last year, the corporation paid out almost $1.8 billion in prizes to winners across Québec. Major prize winners are listed on the Winners page in the Lotteries section of Read their stories. The responsible commercialization of lottery and gaming products is central to Loto-Québec's operations. The corporation has been granted the highest internationally recognized certification in responsible gaming by the World Lottery Association.
Cision Canada
8 hours ago
- Cision Canada
Media advisory - Canada and Sweden advance their collaboration Français
STOCKHOLM, Sweden, Aug. 15, 2025 /CNW/ - The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, will meet with Ebba Busch, Sweden's Deputy Prime Minister and Minister for Energy, Business and Industry in Stockholm to deepen Canada–Sweden relationship. They will be joined by the Honourable Stephen Fuhr, Secretary of State (Defence Procurement), and Pål Jonson, Sweden's Minister for Defence. Date: Monday, August 18, 2025 Time: 8:30 p.m. (Central European Time) Location: Stockholm, Sweden Note to media: This is a media spray only. Photo and video opportunity will be available at the top of the meeting. Members of the media are asked to contact Isabella Orozco-Madison at [email protected] to receive event location details and confirm their attendance. Stay connected SOURCE Innovation, Science and Economic Development Canada
Cision Canada
8 hours ago
- Cision Canada
ZYUS Life Sciences Announces Closing of Second Tranche of Unit Offering
SASKATOON, SK, Aug. 15, 2025 /CNW/ - ZYUS Life Sciences Corporation (the " Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that, further to its press release dated July 29, 2025, it has closed the second tranche (the " Second Tranche") of its non-brokered private placement (the " Offering") of units of the Company (each a " Unit") for up to CAD $1,000,000. Under the Second Tranche of the Offering, a further 140,845 Units were issued for aggregate gross proceeds of CAD $100,000. The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering (which closed on July 29, 2025) (the " First Tranche") is approximately $0.42 million. The Company has issued a total of 591,126 Units each priced at $0.71 per Unit in the First Tranche and the Second Tranche. Each Unit consists of one common share of the Company (a " Common Share") and one Common Share purchase warrant (each Common Share purchase warrant, a " Warrant"), whereby each Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms (the " Acceleration Provision"). In accordance with the Acceleration Provision, if the volume-weighted average trading price of the Common Shares is greater than $3.00 for a period of 5 consecutive trading days on the TSX Venture Exchange (the " TSXV"), the Company will have the right to accelerate the expiry date of the Warrants. Proceeds of the Offering will be used for general corporate and working capital purposes. No finder's fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring November 30, 2025, and all securities issued under the Second Tranche of the Offering are subject to a hold period expiring December 16, 2025, in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, receipt of TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, obtain TSXV final acceptance, closing of any additional tranche of the Offering and use of proceeds from the Offering are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
